Altimmune Sued Over Alleged Misstatements on Pemvidutide Efficacy
Bronstein, Gewirtz & Grossman, LLC has initiated a class action lawsuit against Altimmune, Inc. (NASDAQ: ALT) and its officers on behalf of investors who purchased the company's securities between August 10, 2023 and June 25, 2025. The lawsuit alleges violations of federal securities laws by Altimmune and its officers.
The class action, filed in the Delaware Court of Chancery, challenges Altimmune's public statements regarding the efficacy of Pemvidutide and the likelihood of regulatory success. The complaint alleges that Altimmune downplayed the significance of the IMPACT Phase 2b MASH trial's failure to meet statistical significance in its primary endpoint of fibrosis reduction. Investors who suffered losses in Altimmune have until October 6, 2025, to request the court to appoint them as lead plaintiff. Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits on a contingency fee basis, having previously recovered hundreds of millions of dollars for investors nationwide.
The lawsuit against Altimmune, Inc. is ongoing, with investors who purchased the company's securities during the specified period being urged to take action by October 6, 2025. The outcome of the case will determine the resolution of the alleged securities law violations.
